GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » WDB coco Co Ltd (TSE:7079) » Definitions » EV-to-EBIT

WDB coco Co (TSE:7079) EV-to-EBIT : 6.90 (As of May. 16, 2024)


View and export this data going back to 2019. Start your Free Trial

What is WDB coco Co EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, WDB coco Co's Enterprise Value is 円7,714 Mil. WDB coco Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was 円1,118 Mil. Therefore, WDB coco Co's EV-to-EBIT for today is 6.90.

The historical rank and industry rank for WDB coco Co's EV-to-EBIT or its related term are showing as below:

TSE:7079' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.9   Med: 11.83   Max: 63.11
Current: 6.9

During the past 6 years, the highest EV-to-EBIT of WDB coco Co was 63.11. The lowest was 6.90. And the median was 11.83.

TSE:7079's EV-to-EBIT is ranked better than
87.12% of 427 companies
in the Healthcare Providers & Services industry
Industry Median: 18.24 vs TSE:7079: 6.90

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. WDB coco Co's Enterprise Value for the quarter that ended in Dec. 2023 was 円8,906 Mil. WDB coco Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was 円1,118 Mil. WDB coco Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 12.55%.


WDB coco Co EV-to-EBIT Historical Data

The historical data trend for WDB coco Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WDB coco Co EV-to-EBIT Chart

WDB coco Co Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-EBIT
Get a 7-Day Free Trial - 10.35 15.58 11.60 8.87

WDB coco Co Quarterly Data
Mar18 Mar19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.33 8.87 11.58 9.53 7.97

Competitive Comparison of WDB coco Co's EV-to-EBIT

For the Health Information Services subindustry, WDB coco Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


WDB coco Co's EV-to-EBIT Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, WDB coco Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where WDB coco Co's EV-to-EBIT falls into.



WDB coco Co EV-to-EBIT Calculation

WDB coco Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=7714.084/1117.919
=6.90

WDB coco Co's current Enterprise Value is 円7,714 Mil.
WDB coco Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円1,118 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


WDB coco Co  (TSE:7079) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

WDB coco Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=1117.919/8906.4356
=12.55 %

WDB coco Co's Enterprise Value for the quarter that ended in Dec. 2023 was 円8,906 Mil.
WDB coco Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円1,118 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


WDB coco Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of WDB coco Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


WDB coco Co (TSE:7079) Business Description

Traded in Other Exchanges
N/A
Address
1-8-11 Harumi, Chuo-ku, Triton Square Y 27th Floor, Tokyo, JPN, 104-6127
WDB coco Co Ltd is a provider of safety information management for the development of pharmaceuticals and medical devices. Its services include business related to safety information management, preparation of materials related to regulatory application, QC related work, PMS facility contract support related work, clinical research support / monitoring, and temporary staffing. The company provides Contract Research Organization services for all new drug developments such as monitoring, safety information, data management and statistical analysis. It provides support for the development of generic drugs such as bioequivalence studies and biosimilars, clinical research and physician-led clinical trials.

WDB coco Co (TSE:7079) Headlines

No Headlines